Novartis hands Greenlines PR for Alzheimer’s drug

Novartis, the world’s fourth- largest pharmaceutical firm, has hired Greenlines Healthcare Communications to work on the communications strategy for its Alzheimer’s disease treatment Exelon.

Novartis, the world’s fourth- largest pharmaceutical firm, has

hired Greenlines Healthcare Communications to work on the communications

strategy for its Alzheimer’s disease treatment Exelon.



Greenlines replaces incumbent The Workhouse on the account which was

awarded following a three-way competitive pitch. Board director Ina

Chandler-Brown will head the account for Greenlines, reporting to Exelon

product manager Linda Cockinis; and to Kate Scott, marketing manager,

central nervous system.



Greenlines will target UK healthcare professionals disseminating

clinical data. It will also target the media. The drug is due to go

before the National Institute of Clinical Excellence between July and

December this year, but Greenlines is not involved in that submission.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in